Selective Ghrelin Agonism with Ipamorelin
Pulsatile GH release without cortisol or prolactin elevation in in-vitro models.
- 1Selective GHS-R1a agonist — no cortisol or prolactin elevation in models.
- 2Triggers physiologic-shaped GH pulses rather than tonic release.
- 3Additive with GHRH analogs (CJC-1295, Sermorelin) in combination studies.
- 4Cleanest secretagogue profile in the published GHRP literature.
Selective GHS-R Agonism
Ipamorelin is a pentapeptide growth-hormone secretagogue. What distinguishes it from earlier GHRPs (GHRP-2, GHRP-6) is the cleanliness of its receptor profile — strong GHS-R1a activity with negligible activation of the ACTH or prolactin axes.
Pulsatile Release Pattern
Pituitary cell models exposed to Ipamorelin show a sharp, transient GH pulse that mimics physiologic secretion. This contrasts with continuous-exposure models that drive receptor desensitization and flatten the GH curve.
Combination Research
Ipamorelin is often studied alongside GHRH analogs (CJC-1295, Sermorelin). The two classes act on parallel pathways — GHRH increases the pool of releasable GH, while Ipamorelin triggers the pulse — and combination models show additive GH output.